SG11201605906UA - Muscle-specific nucleic acid regulatory elements and methods and use thereof - Google Patents

Muscle-specific nucleic acid regulatory elements and methods and use thereof

Info

Publication number
SG11201605906UA
SG11201605906UA SG11201605906UA SG11201605906UA SG11201605906UA SG 11201605906U A SG11201605906U A SG 11201605906UA SG 11201605906U A SG11201605906U A SG 11201605906UA SG 11201605906U A SG11201605906U A SG 11201605906UA SG 11201605906U A SG11201605906U A SG 11201605906UA
Authority
SG
Singapore
Prior art keywords
muscle
methods
nucleic acid
regulatory elements
specific nucleic
Prior art date
Application number
SG11201605906UA
Other languages
English (en)
Inventor
Thierry Vandendriessche
Marinee Chuah
Bleser Pieter De
Original Assignee
Univ Bruxelles
Vib Vzw
Univ Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bruxelles, Vib Vzw, Univ Gent filed Critical Univ Bruxelles
Publication of SG11201605906UA publication Critical patent/SG11201605906UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201605906UA 2014-01-21 2015-01-21 Muscle-specific nucleic acid regulatory elements and methods and use thereof SG11201605906UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14151960 2014-01-21
PCT/EP2015/051081 WO2015110449A1 (fr) 2014-01-21 2015-01-21 Éléments régulateurs d'acide nucléique exprimé dans un muscle, méthodes et utilisation associées

Publications (1)

Publication Number Publication Date
SG11201605906UA true SG11201605906UA (en) 2016-08-30

Family

ID=49989567

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605906UA SG11201605906UA (en) 2014-01-21 2015-01-21 Muscle-specific nucleic acid regulatory elements and methods and use thereof

Country Status (9)

Country Link
US (4) US11072801B2 (fr)
EP (2) EP3800261A1 (fr)
JP (4) JP6626829B2 (fr)
AU (2) AU2015208247B2 (fr)
CA (1) CA2936726C (fr)
ES (1) ES2862526T3 (fr)
PL (1) PL3097197T3 (fr)
SG (1) SG11201605906UA (fr)
WO (1) WO2015110449A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2862526T3 (es) * 2014-01-21 2021-10-07 Univ Brussel Vrije Elementos reguladores de ácido nucleico específicos de músculo y métodos y uso de los mismos
KR102474330B1 (ko) * 2014-07-29 2022-12-05 메르크 파텐트 게엠베하 유기 전계발광 소자용 재료
MA45477A (fr) 2016-04-15 2019-02-20 Res Inst Nationwide Childrens Hospital Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
EP3442600B1 (fr) 2016-04-15 2024-03-13 Research Institute at Nationwide Children's Hospital Administration de b-sarcoglycane et de microarn-29 à l'aide d'un vecteur de virus adéno-associé, et traitement de la dystrophie musculaire
EP3293259A1 (fr) * 2016-09-12 2018-03-14 Genethon Variants d'alpha-glucosidase acide et leurs utilisations
CA3053455A1 (fr) 2017-03-10 2018-09-13 Genethon Traitement de la glycogenose de type iii
SG11201908575SA (en) * 2017-03-17 2019-10-30 Res Inst Nationwide Childrens Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
AU2018241847A1 (en) * 2017-03-27 2019-10-17 Vrije Universiteit Brussel Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
WO2019078916A1 (fr) 2017-10-18 2019-04-25 Research Institute At Nationwide Children's Hospital Administration par vecteur à virus adéno-associé de micro-dystrophine spécifique de muscles pour traiter la dystrophie musculaire
US11873347B2 (en) 2017-10-31 2024-01-16 Vib Vzw Antigen-binding chimeric proteins and methods and uses thereof
WO2019153009A1 (fr) * 2018-02-05 2019-08-08 Audentes Therapeutics, Inc. Éléments de régulation de la transcription et utilisations associées
CA3086942A1 (fr) * 2018-02-07 2019-08-15 Genethon Elements regulateurs hybrides
EP3790394A4 (fr) * 2018-05-08 2022-07-27 Rutgers, the State University of New Jersey Protéines de polymérisation de lieur-laminine compatibles avec aav
ES2946415T3 (es) 2018-08-08 2023-07-18 Genethon Mini-GDE para el tratamiento de la enfermedad de almacenamiento de glucógeno III
US20210343368A1 (en) * 2018-09-05 2021-11-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Method for Engineering Synthetic Cis-Regulatory DNA
EP3870215A1 (fr) 2018-10-26 2021-09-01 Vrije Universiteit Brussel Nouveaux outils pour améliorer la thérapie génique, et utilisation correspondante
EP3893940A4 (fr) * 2018-12-12 2022-09-28 Solidus Biosciences, Inc. Polythérapie pour le traitement de la dystrophie musculaire
JP2022529680A (ja) 2019-04-19 2022-06-23 ジェネトン 線維芽細胞増殖因子２３関連低リン血症性疾患の遺伝子療法
MX2022010085A (es) 2020-02-18 2022-09-02 Univ Brussel Vrije Elementos y metodos de regulacion de acidos nucleicos especificos de musculo y uso de los mismos.
CN115298307A (zh) 2020-02-18 2022-11-04 布鲁塞尔自由大学 核酸调节元件的新组合及其方法和用途
KR20220164743A (ko) * 2020-04-06 2022-12-13 호몰로지 메디슨, 인크. Ids 유전자 전달을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법
BR112022020945A2 (pt) * 2020-04-17 2022-12-27 Nevada Res & Innovation Corporation Inibição por crispr para distrofia muscular fácioescápulo- umeral
CA3177954A1 (fr) * 2020-05-14 2021-11-18 James M. Wilson Compositions utiles dans le traitement de la maladie de pompe
EP4200410A1 (fr) 2020-08-24 2023-06-28 Genethon Gde tronqué à terminaison c pour le traitement de la glycogénose iii
WO2022056291A1 (fr) * 2020-09-11 2022-03-17 Nature Technology Corporation Promoteur hybride spécifique des muscles
EP4263828A1 (fr) 2020-12-21 2023-10-25 Vrije Universiteit Brussel Éléments régulateurs d'acide nucléique provenant de cardiomyocytes, méthodes et utilisation associées
EP4294459A1 (fr) * 2021-02-19 2023-12-27 University Of Florida Research Foundation, Incorporated Méthodes et compositions pour conférer une régulation à des charges de thérapie génique par l'utilisation hétérologue de cassettes d'épissage alternatif
AU2022260111A1 (en) 2021-04-20 2023-11-30 Anjarium Biosciences Ag Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
WO2022236296A1 (fr) * 2021-05-05 2022-11-10 The General Hospital Corporation Thérapie pour le traitement du syndrome de prader-willi
KR20240023643A (ko) * 2021-06-23 2024-02-22 신프로믹스 엘티디 조절 핵산 서열
AR126660A1 (es) 2021-07-28 2023-11-01 Univ Brussel Vrije Mejorando la eficacia de la terapia génica dirigida a músculos
WO2023015304A1 (fr) * 2021-08-05 2023-02-09 Insmed Incorporated Particules de virus adéno-associés et leurs procédés d'utilisation
US20230200363A1 (en) * 2021-12-23 2023-06-29 FireFrogs, Inc. Transgenic fluorescent ornamental amphibians
WO2023135273A2 (fr) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions de molécules d'adn codant pour le facteur viii, leurs procédés de préparation et leurs méthodes d'utilisation
CN114231532B (zh) * 2022-02-22 2022-06-17 广州派真生物技术有限公司 在哺乳动物肌肉中特异性启动基因的启动子序列及其应用
US20230346977A1 (en) 2022-04-13 2023-11-02 Universitat Autònoma De Barcelona Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
WO2023237731A1 (fr) 2022-06-09 2023-12-14 Genethon Gde tronquée au niveau du terminal n pour le traitement de la maladie de stockage du glycogène de type iii
WO2024079530A2 (fr) * 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Éléments régulateurs d'acide nucléique aux fins de l'expression génique dans le muscle et procédés d'utilisation
CN115838725B (zh) * 2022-12-30 2023-09-08 广州派真生物技术有限公司 在哺乳动物心脏中特异性启动基因的启动子序列及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127457A (en) * 1872-06-04 Improvement in saw-swages
US503558A (en) * 1893-08-15 Treating pulverulent material with gases
FR2730735B1 (fr) 1995-02-20 1997-05-09 Pasteur Institut Sequences amplificatrices, vecteurs portant ces sequences et leurs utilisations dans des compositions pour l'expression de sequences nucleotidiques dans des cellules transfectees, applications therapeutiques et vaccinales
US20030204075A9 (en) 1999-08-09 2003-10-30 The Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
EP1390490B1 (fr) 2001-05-24 2009-04-15 Genzyme Corporation Vecteurs d'expression specifiques aux muscles
CA2477874A1 (fr) 2002-03-04 2003-09-12 Transgene Sa Cassette d'expression pour la persistance de l'expression d'un gene recherche dans des cellules musculaires
US20080039413A1 (en) * 2003-10-21 2008-02-14 Morris David W Novel compositions and methods in cancer
FR2891544A1 (fr) 2005-09-30 2007-04-06 Genethon Ass Loi De 1901 Substrat proteique pour la detection de l'activite calpaine 3
EP2021499A4 (fr) 2005-12-16 2010-02-17 Univ Leland Stanford Junior Reseaux fonctionnels pour la caracterisation a grande cadence d'elements regulant l'expression genique
WO2008073303A2 (fr) 2006-12-07 2008-06-19 Switchgear Genomics Éléments de régulation transcriptionnelle de voies biologiques, outils, et procédés
US9217020B2 (en) 2007-04-17 2015-12-22 National Research Council Of Canada Constructs for enhancement of gene expression in muscle
EP4154903A1 (fr) * 2008-04-22 2023-03-29 Vib Vzw Éléments régulateurs d'acides nucléiques spécifiques au foie et procédés et leur utilisation
US9353164B2 (en) * 2009-10-29 2016-05-31 Vib Vzw Cardiac-specific nucleic acid regulatory elements and methods and use thereof
CN103421786B (zh) * 2013-04-24 2015-04-22 华中农业大学 鼠肌肉分化时期特异性表达基因启动子的克隆与应用
CN103451284B (zh) 2013-08-22 2015-03-18 中国科学院生物物理研究所 一组人类心肌细胞的新型分子标记物及其应用
ES2862526T3 (es) * 2014-01-21 2021-10-07 Univ Brussel Vrije Elementos reguladores de ácido nucleico específicos de músculo y métodos y uso de los mismos

Also Published As

Publication number Publication date
US11975078B2 (en) 2024-05-07
JP2021168663A (ja) 2021-10-28
AU2021202866A1 (en) 2021-06-03
AU2015208247A1 (en) 2016-08-25
EP3800261A1 (fr) 2021-04-07
EP3097197B1 (fr) 2020-12-16
US20160340693A1 (en) 2016-11-24
AU2015208247B2 (en) 2021-05-27
JP2017505126A (ja) 2017-02-16
JP2020054357A (ja) 2020-04-09
JP6906591B2 (ja) 2021-07-21
JP2023062192A (ja) 2023-05-02
AU2021202866B2 (en) 2023-09-14
EP3097197A1 (fr) 2016-11-30
CA2936726C (fr) 2024-04-30
JP6626829B2 (ja) 2019-12-25
US11072801B2 (en) 2021-07-27
US20210395770A1 (en) 2021-12-23
US20170275649A1 (en) 2017-09-28
US20200407746A1 (en) 2020-12-31
ES2862526T3 (es) 2021-10-07
JP7235806B2 (ja) 2023-03-08
US10731177B2 (en) 2020-08-04
CA2936726A1 (fr) 2015-07-30
PL3097197T3 (pl) 2021-06-28
WO2015110449A1 (fr) 2015-07-30

Similar Documents

Publication Publication Date Title
SG11201605906UA (en) Muscle-specific nucleic acid regulatory elements and methods and use thereof
HRP20190235T1 (hr) Antisensna nukleinska kiselina
HK1253013A1 (zh) 用於條形碼化核酸的系統和方法
DK3134131T3 (en) Nucleic acid vaccines
SG11201704681QA (en) Artificial nucleic acid molecules
PT3159409T (pt) Ácido nucleico anti-sentido para utilização no tratamento da distrofia muscular de duchenne
IL251390B (en) Polysaccharide and nucleic acid formulations that include viscosity-reducing agents
SG11201608605QA (en) Methods and means for enhancing rna production
FI3215147T3 (fi) Hermostoa salpaavia norketamiiniyhdisteitä ja -menetelmiä
PT3094731T (pt) Moléculas de ácido nucleico modificadas por sacárido
GB201507108D0 (en) Nucleic acid construct
GB201408841D0 (en) Nucleic acid processing
GB201507104D0 (en) Nucleic acid construct
GB201407322D0 (en) Gene therapy
GB201405226D0 (en) Nucleic acid preparation method
GB201416293D0 (en) Methods and preparations
HK1243342A1 (zh) 化合物和方法
GB201415674D0 (en) Nucleic acid analysis
SG10202008046UA (en) Nucleic acid oligomers and uses therefor
GB201403359D0 (en) Nucleic acids and uses thereof
GB201403360D0 (en) Nucleic acids and uses thereof
GB201402630D0 (en) Nucleic acid amplification
GB201419299D0 (en) Method for the enrichment of circulating tumour DNA
GB201421109D0 (en) Insert and method